Related Experiment Video
Updated: Jul 24, 2025
09:06
Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
Published on: June 9, 2018
12.2K
Personalising Alzheimer's Disease progression using brain atrophy markers
Serena Verdi1,2, Saige Rutherford3,4, Charlotte Fraza3,4
1Centre for Medical Image Computing, University College London, London, UK.
Medrxiv : the Preprint Server for Health Sciences
|July 3, 2023
Summary
Neuroanatomical normative modeling tracks Alzheimer's Disease (AD) progression using brain imaging. Increased outlier counts in mild cognitive impairment (MCI) predict conversion to AD, aiding early detection.
Area of Science:
- Neuroimaging
- Neurology
- Biostatistics
Background:
- Alzheimer's Disease (AD) presents significant individual variability.
- Neuroanatomical normative modeling offers a method to capture this variability.
- Tracking disease progression in mild cognitive impairment (MCI) and AD is crucial.
Conclusions:
- Regional outlier maps and tOC effectively track individual-level atrophy rates in neurodegenerative diseases.
- This method provides a quantitative approach to monitor disease progression.
- Neuroanatomical normative modeling shows promise for early detection and monitoring of AD.
Related Concept Videos
01:26Alzheimer's Disease: Overview
527
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
527
01:22Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220